Overcoming Graft Rejection in Induced Pluripotent Stem Cell-Derived Inhibitory Interneurons for Drug-Resistant Epilepsy

Overview

Journal Brain Sci

Publisher MDPI

Date 2024 Oct 25

PMID 39452039

Authors

Cameron P Beaudreault

Richard Wang

Carrie Rebecca Muh

Ashley Rosenberg

Abigail Funari

Patty E McGoldrick

Steven M Wolf

Ariel Sacknovitz

Sangmi Chung

Affiliations

Soon will be listed here.

Abstract

Background: Cell-based therapies for drug-resistant epilepsy using induced pluripotent stem cell-derived inhibitory interneurons are now in early-phase clinical trials, building on findings from trials in Parkinson's disease (PD) and Huntington's disease (HD). Graft rejection and the need for immunosuppressive therapy post-transplantation pose potential barriers to more epilepsy patients becoming potential candidates for inhibitory interneurons transplantation surgery.

Objectives: The present literature review weighs the evidence for and against human leukocyte antigen (HLA)-mediated graft rejection in PD and HD and examines the potential advantages and drawbacks to five broad approaches to cell-based therapies, including autologous cell culture and transplantation, in vivo reprogramming of glial cells using viral vectors, allogeneic transplantation using off-the-shelf cell lines, transplantation using inhibitory interneurons cultured from HLA-matched cell lines, and the use of hypoimmunogenic-induced pluripotent stem cell-derived inhibitory interneurons. The impact of surgical technique and associated needle trauma on graft rejection is also discussed.

Methods: Non-systematic literature review.

Results: While cell-based therapies have enjoyed early successes in treating a host of central nervous system disorders, the immunologic reaction against surgical procedures and implanted materials has remained a major obstacle.

Conclusions: Adapting cell-based therapies using iPSC-derived inhibitory interneurons for epilepsy surgery will similarly require surmounting the challenge of immunogenicity.

References

Spatazza J, Leon W, Alvarez-Buylla A . Transplantation of GABAergic interneurons for cell-based therapy. Prog Brain Res. 2017; 231:57-85. PMC: 6263167. DOI: 10.1016/bs.pbr.2016.11.005. View

Alowaysi M, Lehmann R, Al-Shehri M, Baadhaim M, Alzahrani H, Aboalola D . HLA-based banking of induced pluripotent stem cells in Saudi Arabia. Stem Cell Res Ther. 2023; 14(1):374. PMC: 10729375. DOI: 10.1186/s13287-023-03612-0. View

Upadhya D, Hattiangady B, Castro O, Shuai B, Kodali M, Attaluri S . Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration. Proc Natl Acad Sci U S A. 2018; 116(1):287-296. PMC: 6320542. DOI: 10.1073/pnas.1814185115. View

Fine A, Wirrell E . Seizures in Children. Pediatr Rev. 2020; 41(7):321-347. DOI: 10.1542/pir.2019-0134. View

Kwan P, Arzimanoglou A, Berg A, Brodie M, Hauser W, Mathern G . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009; 51(6):1069-77. DOI: 10.1111/j.1528-1167.2009.02397.x. View

Tamargo C, Kant S . Pathophysiology of Rejection in Kidney Transplantation. J Clin Med. 2023; 12(12). PMC: 10299312. DOI: 10.3390/jcm12124130. View

Krystkowiak P, Gaura V, Labalette M, Rialland A, Remy P, Peschanski M . Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One. 2007; 2(1):e166. PMC: 1764859. DOI: 10.1371/journal.pone.0000166. View

Lin H, Li Q, Du Q, Wang O, Wang Z, Akert L . Integrated generation of induced pluripotent stem cells in a low-cost device. Biomaterials. 2018; 189:23-36. DOI: 10.1016/j.biomaterials.2018.10.027. View

Lentini C, dOrange M, Marichal N, Trottmann M, Vignoles R, Foucault L . Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy. Cell Stem Cell. 2021; 28(12):2104-2121.e10. PMC: 8657801. DOI: 10.1016/j.stem.2021.09.002. View

10.

Fitzgerald M, Sotuyo N, Tischfield D, Anderson S . Generation of cerebral cortical GABAergic interneurons from pluripotent stem cells. Stem Cells. 2020; 38(11):1375-1386. DOI: 10.1002/stem.3252. View

11.

Ni P, Noh H, Shao Z, Zhu Q, Guan Y, Park J . Large-Scale Generation and Characterization of Homogeneous Populations of Migratory Cortical Interneurons from Human Pluripotent Stem Cells. Mol Ther Methods Clin Dev. 2019; 13:414-430. PMC: 6495066. DOI: 10.1016/j.omtm.2019.04.002. View

12.

Touma L, Dansereau B, Chan A, Jette N, Kwon C, Braun K . Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission. Epilepsia. 2022; 63(6):1314-1329. DOI: 10.1111/epi.17243. View

13.

Jehi L, Jette N, Kwon C, Josephson C, Burneo J, Cendes F . Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy. Epilepsia. 2022; 63(10):2491-2506. PMC: 9562030. DOI: 10.1111/epi.17350. View

14.

Mallapaty S . Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost. Nature. 2024; 627(8005):709-710. DOI: 10.1038/d41586-024-00809-y. View

15.

Yoshida S, Kato T, Sato Y, Umekage M, Ichisaka T, Tsukahara M . A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med. 2022; 4(1):51-66.e10. DOI: 10.1016/j.medj.2022.10.003. View

16.

Hu X, White K, Olroyd A, DeJesus R, Dominguez A, Dowdle W . Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol. 2023; 42(3):413-423. PMC: 10940156. DOI: 10.1038/s41587-023-01784-x. View

17.

Bravery C . Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense?. Stem Cells Dev. 2014; 24(1):1-10. DOI: 10.1089/scd.2014.0136. View

18.

Li W, Englund E, Widner H, Mattsson B, van Westen D, Latt J . Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A. 2016; 113(23):6544-9. PMC: 4988567. DOI: 10.1073/pnas.1605245113. View

19.

Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A . An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2012; 31(3):458-66. DOI: 10.1002/stem.1293. View

20.

Mundt S, Greter M, Flugel A, Becher B . The CNS Immune Landscape from the Viewpoint of a T Cell. Trends Neurosci. 2019; 42(10):667-679. DOI: 10.1016/j.tins.2019.07.008. View